Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL.
Journal
Gene therapy
ISSN: 1476-5462
Titre abrégé: Gene Ther
Pays: England
ID NLM: 9421525
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
21
01
2019
accepted:
25
06
2020
revised:
05
01
2020
pubmed:
17
7
2020
medline:
19
8
2021
entrez:
17
7
2020
Statut:
ppublish
Résumé
The SERCA-LVAD trial was a phase 2a trial assessing the safety and feasibility of delivering an adeno-associated vector 1 carrying the cardiac isoform of the sarcoplasmic reticulum calcium ATPase (AAV1/SERCA2a) to adult chronic heart failure patients implanted with a left ventricular assist device. The SERCA-LVAD trial was one of a program of AAV1/SERCA2a cardiac gene therapy trials including CUPID1, CUPID 2 and AGENT trials. Enroled subjects were randomised to receive a single intracoronary infusion of 1 × 10
Identifiants
pubmed: 32669717
doi: 10.1038/s41434-020-0171-7
pii: 10.1038/s41434-020-0171-7
pmc: PMC7744277
doi:
Substances chimiques
Sarcoplasmic Reticulum Calcium-Transporting ATPases
EC 3.6.3.8
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
579-590Subventions
Organisme : British Heart Foundation
ID : SP/09/007/27920
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/16/2/32004
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/13/34/30173
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/16/3/32175
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/15/3/31047
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Références
Lyon AR, Nikolaev VO, Miragoli M, Sikkel MB, Paur H, Benard L, et al. Plasticity of surface structures and beta(2)-adrenergic receptor localization in failing ventricular cardiomyocytes during recovery from heart failure. Circ Heart Failure. 2012;5:357–65. https://doi.org/10.1161/circheartfailure.111.964692
doi: 10.1161/circheartfailure.111.964692
pubmed: 22456061
Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Therapy. 2008;15:1550–7. https://doi.org/10.1038/gt.2008.120
doi: 10.1038/gt.2008.120
pubmed: 18650850
Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am College Cardiol. 2008;51:1112–9. https://doi.org/10.1016/j.jacc.2007.12.014
doi: 10.1016/j.jacc.2007.12.014
Sakata S, Lebeche D, Sakata N, Sakata Y, Chemaly ER, Liang LF, et al. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol. 2007;42:852–61. https://doi.org/10.1016/j.yjmcc.2007.01.003
doi: 10.1016/j.yjmcc.2007.01.003
pubmed: 17300800
pmcid: 1945057
del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey JK, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation. 2001;104:1424–9.
doi: 10.1161/hc3601.095574
Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK, et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA. 1998;95:5251–6.
doi: 10.1073/pnas.95.9.5251
Lyon AR, Bannister ML, Collins T, Pearce E, Sepehripour AH, Dubb SS, et al. SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circulation Arrhythmia Electrophysiol. 2011;4:362–72. https://doi.org/10.1161/circep.110.961615
doi: 10.1161/circep.110.961615
Cutler MJ, Wan X, Plummer BN, Liu H, Deschenes I, Laurita KR, et al. Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery to restore electrical stability in the failing heart. Circulation. 2012;126:2095–104. https://doi.org/10.1161/circulationaha.111.071480
doi: 10.1161/circulationaha.111.071480
pubmed: 23019291
pmcid: 3538142
del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100:2308–11.
doi: 10.1161/01.CIR.100.23.2308
Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304–13. https://doi.org/10.1161/circulationaha.111.022889
doi: 10.1161/circulationaha.111.022889
pubmed: 21709064
pmcid: 5843948
Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circulation Res. 2014;114:101–8. https://doi.org/10.1161/circresaha.113.302421
doi: 10.1161/circresaha.113.302421
pubmed: 24065463
Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016;387:1178–86. https://doi.org/10.1016/s0140-6736(16)00082-9
doi: 10.1016/s0140-6736(16)00082-9
pubmed: 26803443
Hulot JS, Salem JE, Redheuil A, Collet JP, Varnous S, Jourdain P, et al. Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial. Eur J Heart Failure. 2017;19:1534–41. https://doi.org/10.1002/ejhf.826
doi: 10.1002/ejhf.826
Crespo-Leiro, MG, Metra, M, Lund, LH, Milicic, D, Costanzo, MR, Filippatos, G et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1236 (2018).
Terracciano CM, Hardy J, Birks EJ, Khaghani A, Banner NR, Yacoub MH. Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation. 2004;109:2263–5. https://doi.org/10.1161/01.cir.0000129233.51320.92
doi: 10.1161/01.cir.0000129233.51320.92
pubmed: 15136495
Greenberg B, Yaroshinsky A, Zsebo KM, Butler J, Felker GM, Voors AA, et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC. Heart Failure. 2014;2:84–92. https://doi.org/10.1016/j.jchf.2013.09.008
doi: 10.1016/j.jchf.2013.09.008
pubmed: 24622121
George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377:2215–27. https://doi.org/10.1056/NEJMoa1708538
doi: 10.1056/NEJMoa1708538
pubmed: 29211678
pmcid: 6029626
Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713–22. https://doi.org/10.1056/NEJMoa1706198
doi: 10.1056/NEJMoa1706198
pubmed: 29091557
Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, et al. AAV5-factor viii gene transfer in severe hemophilia A. N Engl J Med. 2017;377:2519–30. https://doi.org/10.1056/NEJMoa1708483
doi: 10.1056/NEJMoa1708483
pubmed: 29224506
Williams DA, Eichler F, Duncan C. Gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2018;378:490–1. https://doi.org/10.1056/NEJMc1715427
doi: 10.1056/NEJMc1715427
pubmed: 29385368
Hinderer, C, Katz, N, Buza, EL, Dyer, C, Goode, T, Bell, P et al. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther., https://doi.org/10.1089/hum.2018.015 (2018).